ZVRA Earnings Prediction
The chart below shows how ZVRA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ZVRA sees a +1.25% change in stock price 10 days leading up to the earnings, and a -0.30% change 10 days following the report. On the earnings day itself, the stock moves by -2.48%. This data can give you a slight idea of what to expect for the next quarter's release.
ZVRA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.69M
27.63%
-16.95%
Gross Margin
-4.14%
-104.36%
-72.51%
Operating Margin
-739.00%
39.25%
38.17%
Net Margin
-899.19%
151.10%
100.78%
EPS
-0.69
-130.00%
43.75%
No Data Available
ZVRA Earnings Analysis
Zevra Therapeutics, Inc. Common Stock Corporation (ZVRA.O) Earnings Conference Call
Positive
Third Quarter Net Revenue: Zevra Therapeutics reported a net revenue of $3.7 million in the third quarter, including $2.6 million in net reimbursements from the French EAP for arimoclomol and $1.1 million of royalties and other reimbursements under the AZSTARYS license.
MIPLYFFA Launch Success: The launch of MIPLYFFA has exceeded expectations with 90 prescription enrollment forms submitted as of October 31, indicating strong market interest and demand.
Public Offering Success: The company completed an underwritten public offering of more than 10.6 million shares of common stock at a price of $6.50 per share, raising approximately $64.5 million after deducting underwriting discounts and offering expenses.
Cash and Investments Increase: As of September 30, total cash, cash equivalents, and investments were $95.5 million, an increase of $46.2 million compared to June 30 of this year, providing a strong financial foundation for future growth.
Clinical Trial Progress: The company has made significant progress in its clinical trials, with a high level of engagement from patient advocacy groups, enhancing awareness and support for its therapies.
Negative
Quarterly Net Loss Comparison: The net loss for the third quarter was $33.2 million, or $0.69 per basic and diluted share, compared to $10.4 million, or $0.30 per basic and diluted share in the same quarter a year ago.
R&D Expense Increase: R&D expenses for the third quarter were $10.9 million, which was an increase of 4% compared to the second quarter of this year.
SG&A Expense Increase: Selling, general and administrative expenses were $16.2 million during the third quarter, representing an increase of 28.6% from the second quarter of this year.
Third Quarter Net Revenue: Net revenue for the third quarter was reported at $3.7 million, which includes $2.6 million in net reimbursements from the French EAP for arimoclomol and $1.1 million of royalties and other reimbursements under the AZSTARYS license.
Enrollment Decline and Revenue Impact: We saw new enrollments decrease to three in the third quarter from nine in the second quarter, and revenue was diminished.
ZVRA FAQs
How does ZVRA typically perform around its earnings report dates?
Is Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ZVRA Earning Call Sentiment
Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ZVRA.O
4.55%Positive
The earnings call summary shows mixed signals. While there are positive developments such as increased revenue, extended cash runway, and strong patient demand for trials, there are concerns about rising expenses, increased net loss, and management's reluctance to provide guidance. The Q&A section highlights uncertainties in patient reimbursement and competition. These factors balance out the positive aspects, leading to a neutral sentiment prediction.
